Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates

被引:45
|
作者
Stolk, LML
Degraeuwe, PLJ
Nieman, FHM
de Wolf, MC
de Boer, A
机构
[1] Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[2] Univ Hosp Maastricht, Dept Clin Epidemiol, Maastricht, Netherlands
[3] Univ Hosp Maastricht, Dept Pediat, Maastricht, Netherlands
[4] Univ Hosp Maastricht, Dept Clin Pharm, Maastricht, Netherlands
关键词
newborn; gentamicin pharmacology; population pharmacokinetics; predictors; multiple regression analysis;
D O I
10.1097/00007691-200208000-00011
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Population pharmacokinetic parameter estimates were calculated from 725 routine plasma gentamicin concentrations obtained in 177 neonates of 24 to 42 weeks' gestational age in their first week of life. K-el increases and V/W decreases with increasing gestational age. Almost identical results were obtained with iterative two-stage Bayesian fitting (MW\PHARM 3.30) as with a non-parametric maximization algorithm (NPEM2). The effect of various covariates on drug disposition was investigated retrospectively using multiple regression analysis. Predictive power for K-el increases with rising gestational age. For neonates less than or equal to28.5 weeks and neonates >28.5 weeks and less than or equal to30.9 weeks, the predictive power of the regression equation for Kel was relatively low (r(2) respectively 0.270 and 0.364). Better predictivity was found for K., at gestational ages >30.9 weeks (r(2) = 0.482), with gestational age, postnatal age, and Apgar score at 5 minutes being predictors. A very strong correlation existed between volume of distribution and weight (r(2) = 0.83). Volume as a function of weight could be described with low predictivity by gestational age and to a lesser degree by Apgar score at 5 minutes (r(2) = 0.298). The developed models need appropriate prospective clinical validation.
引用
收藏
页码:527 / 531
页数:5
相关论文
共 50 条
  • [1] POPULATION PHARMACOKINETICS OF GENTAMICIN IN NEONATES
    THOMSON, AH
    WAY, S
    BRYSON, SM
    MCGOVERN, EM
    KELMAN, AW
    WHITING, B
    DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1988, 11 (03): : 173 - 179
  • [2] POPULATION PHARMACOKINETICS OF GENTAMICIN IN NEONATES USING ROUTINE CLINICAL-DATA
    GRASELA, TH
    OTT, R
    FAIX, RG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 199 - 199
  • [3] Clinical pharmacokinetics in optimal gentamicin dosing regimen in neonates
    Vucicevic, Katarina M.
    Rakonjac, Zorica M.
    Jankovic, Borisav Z.
    Kovacevic, Sandra D. Vezmar
    Miljkovic, Branislava R.
    Prostran, Milica S.
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2014, 9 (03): : 485 - 490
  • [4] Population Pharmacokinetics and Dosing of Gentamicin and Tobramycin in Neonates: A Scoping Review
    Lim, Y. H.
    Chung, E.
    Seto, W.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2024, 77 (02):
  • [5] POPULATION-MODEL FOR GENTAMICIN PHARMACOKINETICS IN INFANTS AND NEONATES USING NPEM
    GILMAN, TM
    STEINBERG, I
    YOSHIDA, TM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 157 - 157
  • [6] Population pharmacokinetics of gentamicin in horses
    Martín-Jiménez, T
    Papich, MG
    Riviere, JE
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1998, 59 (12) : 1589 - 1598
  • [7] Gentamicin pharmacokinetics in neonates with patent ductus arteriosus
    VandenAnker, JN
    Kearns, GL
    CRITICAL CARE MEDICINE, 1997, 25 (11) : 1933 - 1934
  • [8] Gentamicin Pharmacokinetics in Neonates Undergoing Therapeutic Hypothermia
    Mark, Liana F.
    Solomon, Addishiwot
    Northington, Frances J.
    Lee, Carlton K. K.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (02) : 217 - 222
  • [9] PHARMACOKINETICS OF GENTAMICIN DURING EXCHANGE TRANSFUSIONS IN NEONATES
    KLIEGMAN, RM
    BERTINO, JS
    FANAROFF, AA
    GAVAN, TL
    SPECK, WT
    JOURNAL OF PEDIATRICS, 1980, 96 (05): : 927 - 930
  • [10] The effect of postnatal age on gentamicin pharmacokinetics in neonates
    Knight, JA
    Davis, EM
    Manouilov, K
    Hoie, EB
    PHARMACOTHERAPY, 2003, 23 (08): : 992 - 996